All In Biotech

Drug Trial Radar · NCT00974571

Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study Investigating the Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis

Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,365 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,365

Actual

Start

Nov 2001

Primary completion

May 2002

Study completion May 2002

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Sep 10, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the ability of montelukast to improve the signs and symptoms of perennial allergic rhinitis compared to placebo. Cetirizine is included in the study as an active control.

Conditions

  • Perennial Allergic Rhinitis

Interventions

  • montelukast sodiumDrug

    montelukast 10 mg tablet orally once daily at bedtime for 6 weeks

  • Comparator: cetirizineDrug

    cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks

  • Comparator: placeboDrug

    placebo tablet orally once daily at bedtime for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Daytime Nasal Symptoms ScoreTime frame: Baseline and first 4 weeks of a 6-week treatment period

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.